3-Iodo-5-chloro-N-[2-chloro-5-((4-chlorophenyl)sulphonyl)phenyl]-2-hydroxybenzamide | 315195-18-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Iodo-5-chloro-N-[2-chloro-5-((4-chlorophenyl)sulphonyl)phenyl]-2-hydroxybenzamide
• 英文别名: 5-chloro-N-[2-chloro-5-(4-chlorophenyl)sulfonylphenyl]-2-hydroxy-3-iodobenzamide
• CAS: 315195-18-7
• 化学式: C₁₉H₁₁Cl₃INO₄S
• mdl: MFCD00560024
• 分子量: 582.6
• InChiKey: XGTQWEPDCQCNBF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Chemical entities that kill senescent cells for use in treating age-related disease
  申请人：Unity Biotechnology, Inc.

  公开号：US10195213B2

  公开（公告）日：2019-02-05

  Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.

  本文公开的化合物可有效治疗与衰老有关的各种疾病状态。所公开的化合物可用于消除衰老细胞以治疗疾病。化合物的给药方式包括单次给药和循环给药。
• Method for producing hypertrophic scarring animal model for identification of agents for prevention and treatment of human hypertrophic scarring
  申请人：Gurtner C. Geoffrey

  公开号：US20060037091A1

  公开（公告）日：2006-02-16

  The present invention relates to a method of producing a non-human animal model of hypertrophic scarring. This involves producing an incision in a non-human animal and applying mechanical strain over the incision under conditions effective to produce hypertrophic scarring, thereby producing a non-human animal model of hypertrophic scarring. The present invention also relates to a method of determining the efficacy of an agent for prevention or treatment of a disease condition. This method involves providing a non-human animal having an incision over which mechanical strain is applied under conditions effective to produce hypertrophic scarring, administering an agent to the incision, and determining whether the agent is efficacious for prevention or treatment of a disease condition. Also provided is a non-human animal model of hypertrophic scarring. This involves a non-human animal having an incision over which mechanical strain has been applied under conditions effective to produce hypertrophic scarring.

  本发明涉及一种制作非人类动物增生性瘢痕模型的方法。这包括在非人类动物身上制作切口，并在有效产生增生性瘢痕的条件下对切口施加机械应变，从而制作出增生性瘢痕的非人类动物模型。本发明还涉及一种确定预防或治疗疾病药剂疗效的方法。该方法包括提供一种非人类动物，该动物有一个切口，在有效产生增生性瘢痕的条件下，在该切口上施加机械应变，在该切口上施用一种药剂，并确定该药剂是否具有预防或治疗疾病的功效。此外，还提供了一种增生性瘢痕的非人类动物模型。这涉及到非人类动物的切口，在有效产生增生性瘢痕的条件下，在切口上施加机械应变。
• CANCER THERAPY USING BCL-XL-SPECIFIC SINA
  申请人：Centre Régional de Lutte contre le Cancer - Centre François Baclesse

  公开号：EP2038414A2

  公开（公告）日：2009-03-25
• CANCER THERAPY USING Bcl-XL-SPECIFIC siNA
  申请人：Poulain Laurent

  公开号：US20130237584A1

  公开（公告）日：2013-09-12

  The invention relates to a double-stranded short interfering nucleic acid (siNA) molecule specific to the Bcl-X L transcript, comprising a sense and an antisense region, wherein the sense region comprises the nucleotide sequence SEQ ID NO: 1 or a sequence having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with said sequence, and the antisense region comprises a nucleotide sequence that is complementary to the sense region, and its use for treating cancer.
• COMPOUNDS AND THERAPEUTIC USES
  申请人：Unity Biotechnology, Inc.

  公开号：US20170281649A1

  公开（公告）日：2017-10-05

  Disclosed herein are compounds that are effective for treatment of various disease states associated with senescence. The disclosed compounds can be used to eliminate senescent cells for disease treatment. The dosing of the compounds includes both single administration and regimens of cycling dosages.